BeNeLuxBelgiumNetherlandsLuxembourg

Camelid-derived antibody alliance

06.02.2011

Rotterdam – Biopharmaceutical company arGEN-X BV has entered into an alliance that will generate monoclonal antibody candidates against diverse functional sites in targets from Eli Lilly and Co. Founded in 2008, the Dutch biotech firm has developed the SIMPLE antibody platform, which is based on the discovery that the variable domains of certain antibodies from camelids like llamas are very similar to their human counterparts. arGEN-X’s platform involves the active immunisation of out-bred camelids with targets to generate antibodies whose variable regions are virtually identical in stucture and sequence to human antibodies. The out-bred animals provide a greater diversity of mAbs than in-bred animal platforms.
In a further step, arGEN-X is combining selected variable domains of human antibodies to generate full-size, human thera­peutical antibodies as development candidates. Lilly will have exclusive rights to develop and commercialise selected candidates, while arGEN-X will receive research funding and license fees, and is eligible for potential milestone payments. Further terms were not disclosed. The most advanced human monoclonal antibody candidate from the SIMPLE platform so far is ARGX-109, which targets IL-6 – a cytokine involved in autoimmune diseases and oncology indications. arGEN-X said an investigational new drug application is slated to be filed this year. The company also claimed it is in negotiations with a number of potential partners for the product.

BeNeLuxBelgiumNetherlandsLuxembourg

29.03.2012

Brussels – Promethera Biosciences has completed a Series B financing round, generating proceeds of €23.6m. The Belgian cell therapy company secured a capital increase of €17m from its new investors, among them the venture arms...

BeNeLuxBelgiumNetherlandsLuxembourg

19.03.2012

Leuven – Biopharmaceutical company ThromboGenics has entered into an agreement with Alcon Inc., a division of Novartis for the commercialisation of its product ocriplasmin in all markets outside the U.S. ThromboGenics said it...

BeNeLuxBelgiumNetherlandsLuxembourg

07.03.2012

Amsterdam Molecular Therapeutics has announced a financial manoeuvre aimed at getting the biotech out of a hopeless situation. The assets and – more importantly – the liabilities of the drug developer will be acquired by a newly...

BeNeLuxBelgiumNetherlandsLuxembourg

20.02.2012

Amsterdam - Amsterdam Molecular Therapeutics has announced a financial manoeuvre which is aimed to get the biotech out of a dead end. The assets and – more importantly – the liabilities of the drug developer will be acquired by...

BeNeLuxBelgiumNetherlandsLuxembourg

10.02.2012

Glasgow/Leuven - With a little help from the EU, two biotech companies are banding together to develop the first stem cell therapy against rheumatoid arthritis. UK-based Sistemic will work with TiGenix to develop the Belgian's...

BeNeLuxBelgiumNetherlandsLuxembourg

25.01.2012

Amsterdam – Two elephants in the biofuels business join forces. Dutch food and chemicals group Royal DSM and POET, LLC, a US-based ethanol producer, announced a plan to build a commercial cellulosic ethanol plant. POET–DSM...

BeNeLuxBelgiumNetherlandsLuxembourg

13.01.2012

Heerlen - Royal DSM N.V will be the industrial partner to the Panoptes consortium, which aims to develop novel drug delivery technology for the posterior eye segment. The four year project is supported by EUR4m in funding from...

BeNeLuxBelgiumNetherlandsLuxembourg

04.01.2012

Leiden - Dutch Pharming Group NV has taken a further step to secure sound financing even beyond the recent milestone payments. The drug developer announced that it has entered into a financing of approximately €8.4 million by...

BeNeLuxBelgiumNetherlandsLuxembourg

16.12.2011

Ghent – Just days after US pharmaceuticals giant Pfizer pulled out of a rheumatoid arthritis pact with Ablynx NV, the Belgian biopharmaceutical company expanded its relationship with Merck Serono. Ablynx has now entered into a...

Displaying results 1 to 10 out of 304

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-benelux/article/camelid-derived-antibody-alliance.html

Events

All Events

Stock list

All quotes

TOP

  • LONZA107.50 CHF3.46%
  • MORPHOSYS72.46 EUR2.96%
  • SANTHERA95.00 CHF2.48%

FLOP

  • 4SC1.18 EUR-4.07%
  • CYTOS0.25 CHF-3.85%
  • BIOFRONTERA2.32 EUR-3.33%

TOP

  • SANTHERA95.00 CHF58.6%
  • EPIGENOMICS3.72 EUR16.2%
  • BB BIOTECH147.00 EUR13.6%

FLOP

  • BIOFRONTERA2.32 EUR-13.4%
  • WILEX2.36 EUR-12.6%
  • MEDIGENE4.30 EUR-11.3%

TOP

  • SANTHERA95.00 CHF3715.3%
  • CO.DON2.46 EUR207.5%
  • PAION2.41 EUR153.7%

FLOP

  • CYTOS0.25 CHF-93.7%
  • THERAMETRICS0.08 CHF-42.9%
  • MERCK KGAA66.45 EUR-42.3%

No liability assumed, Date: 02.09.2014


Current issue

All issues

Product of the week

Products